Register
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor |
Journal Updates
eMediNexus Coverage from: 
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
eMediNexus,  27 November 2018
remove_red_eye 667 Views
#Hematology #Oncology #Pathology and Lab Medicine

1 Read Comments                

The US Food and Drug Administration has granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second time the agency has approved a cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where the tumor originated. The approval marks a new paradigm in the development of cancer drugs tha
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!